










































siRNA as a tool for investigating organogenesis
Citation for published version:
Lee, W-C, Berry, R, Hohenstein, P & Davies, J 2008, 'siRNA as a tool for investigating organogenesis: The
pitfalls and the promises' Organogenesis, vol. 4, no. 3, pp. 176-181. DOI: 10.4161/org.4.3.6642
Digital Object Identifier (DOI):
10.4161/org.4.3.6642
Link:
Link to publication record in Edinburgh Research Explorer
Document Version:




Copyright © 2008 Landes Bioscience
General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.
Download date: 05. Apr. 2019
Removing the function of a specific gene from a developing 
organ, by making a ‘knockout’ mouse, is a powerful method for 
analyzing the molecular pathways that control organogenesis. The 
technique is expensive, though, in terms of time and money, and 
complex strategies for producing conditional knockouts are needed 
for genes that are essential for early development of the embryo, for 
which an unconditional knockout would be lethal before the organ 
of interest begins to form. Small interfering RNAs (siRNAs) offer 
a method of knocking down the expression of specific genes with 
no need for genomic manipulation. Almost as soon as they had 
been discovered, siRNAs began to be used to explore the molecular 
biology of mammalian cells in conventional, two-dimensional 
culture. They have now also been applied successfully, by several 
groups, to knock down specific genes in various organ rudiments 
developing in organ culture. This article reviews the basic technique 
of siRNA-mediated gene knockdown and how it is being applied 
to organ culture. It also reviews some of the current problems and 
challenges in the field, and the ways in which these problems are 
likely to be overcome.
Introduction
One of the standard methods of investigating the functions of a 
gene or protein in development is to remove it from a developing 
system and to see what happens. This general technique has proved 
to be one of the most powerful in modern biology, and is largely 
responsible for our current understanding of the molecular basis of 
organogenesis.
Removal of gene function is normally achieved by mutation, 
nowadays usually achieved by artificial gene targeting. In mice, 
now the most frequently used organism in developmental biology 
research,1 the most common method of artificial gene targeting is 
by homologous recombination in ES cells.2-6 When done properly 
and after breeding of the engineered mice, this technique succeeds 
in completely removing the gene from the organism. In some 
contexts this is an advantage—it helps to produce, for example, 
unambiguous results—but in other contexts it is a decided disad-
vantage. Organogenesis begins, by definition, right at the end of the 
embryonic period of development (the presence of growing organs 
defines the developing animal as a fetus). Deletion of any gene that is 
required for embryonic development can mean that the foetal stage is 
never reached and the role of that gene in organ development cannot 
be addressed in a simple knockout animal. 
The problem of early deleterious effects of a knockout on embry-
onic development can be solved by making conditional knockout 
animals. The dominant method for this is the cre-lox system.7 In this 
technique, the gene of interest is flanked with lox-P sites in a manner 
that does not interfere with the function of that gene. Separately (and 
usually in a different colony of animals, that can later be crossed with 
those carrying the lox-P-flanked gene), the open reading frame of a 
‘driver’ gene is replaced by cre recombinase. As the animal carrying 
this develops, cre recombinase will be expressed in any cell in which 
the driver gene is normally expressed. When both of these systems are 
present in the same animal, the cre recombinase causes recombina-
tion of the lox-P sites and causes deletion of the gene of interest. By 
choosing a driver gene that is expressed only in the organ of interest 
at the time of interest, an experimenter can arrange for the targeted 
gene to be deleted only where the driver gene is activated, and there-
fore avoid the problem of embryonic lethality. 
Conditional knockouts have proved very useful in studies of 
organogenesis8-12 but even this powerful technique has its problems. 
Fundamentally, as the real complexity of the genome due to alterna-
tive splicing events is beginning to be realized thanks to the different 
genome and transcriptome sequencing programs, identifying and 
generating the mutation most likely to result in complete deletion of 
all functional isoforms becomes more problematic. This issue affects 
conventional and conditional knockouts alike. Technically, there is 
the problem that it can be used only when a suitable driver gene can 
be identified; at later stages of organogenesis many tissue-specific 
genes tend to be activated but at earlier stages there are few genes that 
are expressed in one organ and that are not also expressed elsewhere 
in the body and earlier in embryogenesis. Alternatively, tissue-specific 
enhancers can sometimes be identified in the regulatory sequences 
of driver genes, which can be used in combination with a minimal 
promoter to express cre as an ectopic transgenic construct. However, 
taking enhancer elements outside their normal context can result in 
unexpected results and big differences between individual lines, and 
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too often this approach results in a ‘hit-or-miss’ project. Practically, 
there is also the problem of the expense, in terms of both time and 
money, of creating two strains of engineered mice and of breeding 
them together. 
Non-genetic methods for removing the function of specific genes 
are also available, at least for some genes and stages of development. 
Many organ rudiments will develop in organ culture, at least through 
their early stages, and culture techniques have been used with great 
effect to study kidneys, salivary glands, lungs, prostates etc. Organ 
culture renders the rudiment accessible to drugs, antibodies and 
enzymes and these can be used to inhibit the actions of gene prod-
ucts at any time of an experimenter’s choosing. Their use is, however, 
limited to a fairly narrow range of targets. Antibodies and enzymes 
can target only extracellular molecules. Many drugs can act on intra-
cellular targets but they suffer from the problems of relative, rather 
than absolute, specificities and drugs are available to inhibit only a 
tiny subset of the more than 30,000 genes in the genome.
What is urgently needed is a method of inhibiting the expres-
sion of specific genes that can be used in organ culture and that can 
be applied to a very large range of possible targets. The properties 
of small interfering RNAs (siRNAs) seem, at least at first sight, to 
meet this requirement and they have already been used successfully 
in some systems. They are not yet, however, living up to their full 
apparent promise and this review is intended to provide a balanced 
evaluation of their current potential and an overview of the problems 
still to be addressed.
siRNAs and RNA Interference in Conventional (Monolayer) 
Culture
RNA interference is a system for the post-transcriptional repres-
sion of gene expression and it has been reviewed extensively 
elsewhere.13 Briefly, siRNAs consist of a duplex of ≈22-nt RNAs, the 
5´ 20 bases of which are complementary so that the duplex formed 
has two projecting nucleotides at each 3´ end.14,15 If introduced 
into the cytoplasm of a cell, a siRNA is bound by an RNA-induced 
silencing complex (RISC).16 Unwinding of the siRNA duplex when 
it binds to the RISC creates an active form of the RISC complex, 
carrying one strand of the siRNA, which can bind to any mRNA 
with a sequence complementary to that strand. Once bound, the 
RISC complex cleaves the mRNA (Fig. 1). The reaction does 
not destroy the original siRNA strand bound in the RISC, so the 
complex can go on to destroy other complementary mRNAs. In 
this way, low concentrations of siRNA can be effective in silencing 
large numbers of mRNA molecules, at least in principle. Also, with 
careful selection of sequences, siRNA can be used to knock down 
only mRNAs encoding specific splice forms of a gene.
From an experimenter’s point of view, siRNAs can be synthesized 
chemically, can be made by RNase III cleavage of longer double-
stranded RNAs made from plasmids, or from a palindromic sequence 
downstream of a polymerase III promoter in a plasmid or virus that 
is transfected into the cell (the palindrome results in the formation 
of a double-stranded RNA hairpin loop that is cut by the cell into 
siRNA). The choice of method is dictated largely by considerations 
of economics (chemical synthesis is convenient but expensive, yet it 
might in the end be advantageous to compare siRNAs from different 
companies to get optimal knockdown efficiencies), accessibility 
(viruses may diffuse less well than small siRNAs) and the cell type 
involved (some are difficult to transfect). It also depends on the 
desired duration of gene silencing, transient transfection with siRNA 
usually providing a few days’ silencing but permanent integration 
of a plasmid or virus providing permanent knockdown. Inducible 
systems for stably transfected siRNA expression constructs have been 
described that are regulated by tetracycline17,18 using modified RNA 
polymerase III promoters. More versatile control of knockdown 
is to be expected from the observation that custom siRNA target 
sequences can be placed in the backbone of an endogenous micro 
RNA (miRNA) which can be expressed from any RNA polymerase 
II promoter.19,20
Of these common methods of transfection, only the viral method 
allows efficient uptake in mammalian cells without the need for 
transfection reagents: mammalian cells do not, in general, show the 
ability of some invertebrates, such as Caenorhabditis elegans, to take 
up dsRNA without transfection reagents.21 Naked siRNAs (whether 
synthesized chemically or made from dsRNAs) and siRNA-encoding 
plasmids have to be complexed with transfection reagents before they 
Figure 1. The basic mechanism of siRNA-mediated RNA interference. siRNA 
duplexes complexed with a transfection vehicle (pink) are taken across the 
cell membrane by the vehicle. There, they are bound by the RISC complexes 
and become single-stranded and active. The siRNA strand in an active RISC 
complex binds to complementary bases of its target mRNA and the RISC 
complex then cleaves that mRNA.
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will cross cell membranes. A variety of such reagents is available from 
commercial suppliers. The efficiency of each seems to vary between 
cell types, and must be determined empirically. In general, siRNA is 
made into a complex with its transfection reagent and is then applied 
in a suspension on cells in subconfluent two-dimensional culture, 
left for a few hours, then washed away. The inertness of the transfec-
tion reagents used should not be taken for granted, however; at the 
very least, some can modulate the stabilities of RNAs to which they 
are bound and apparently target them to particles in the cytoplasm 
where they may not fulfil their intended functions.22
Supported by adequate controls,23 the use of siRNA in conven-
tional two-dimensional cell culture has proved a very valuable 
technique in a range of cell biological and physiological inves-
tigations.24-28 It is therefore natural to think of extending it to 
three-dimensional organ culture.
Successful Application of siRNA to Organ Culture: The Promise
In principle, the combination of exogenously-applied siRNAs and 
organs growing in culture should be a powerful method for knocking 
down the expression of any gene of interest at any time of an experi-
menter’s choosing. The first published practical demonstration of 
this was produced by Takayoshi Sakai and colleagues, who used olig-
ofectamine to transfect cultured salivary glands from E12.5 mouse 
embryos with 500 nM synthetic siRNA duplexes.29 Control duplexes 
had no significant effect on either morphogenesis or on gene expres-
sion, but siRNAs targeting fibronectin caused decrease in fibronectin 
expression, as judged by immunostaining, and a dramatic, dose-
dependent and reversible inhibition of epithelial branching. A similar 
phenotype was also produced by function-blocking anti-fibronectin 
antibodies. In principle, the entire experiment could have been done 
using the antibodies, but what made the study so powerful from the 
point of view of introducing siRNA as a technique for organogenesis 
was the demonstration that it would replicate the effect of established 
techniques, such as antibody inhibition, so exactly. In the same paper 
(or at least, in the supplementary information provided alongside 
it), the authors used the same siRNAs to knock down the expres-
sion of fibronectin in both cultured embryonic kidneys and cultured 
embryonic lungs, and obtained a very similar general effect.
In the next application of siRNA technology to cultured kidneys, 
another group used an siRNA technique similar to that described 
above to target a protein that was intracellular and therefore unreach-
able by antibodies. 30 The protein, WT1, had already been identified 
as being a tumor suppressor; the mutation of which was implicated 
in the development of the childhood nephroblastoma, Wilms’ 
tumor.31,32 It was known to be expressed in a complex pattern that 
changed as kidney development proceeded33 and a simple transgenic 
deletion of the gene in mice turned out to result in renal agenesis 
rather than development of the tumor. 34 A technique for removing 
Wt1 function at different stages of renal development was therefore 
required to find the stage at which Wt1 loss might be connected with 
tumorigenesis rather than causing renal agenesis. 
Synthetic siRNA duplexes, again complexed with oligofectamine, 
were first applied to cultured E9.5 urogenital ridges, which are the 
parts of the embryos in which kidneys would form approximately 
one day later. The siRNA prevented the expression of WT1 protein 
in most cells, as judged by immunofluorescence, and produced a 
renal agenesis phenocopy of the Wt1 knockout mouse. Application 
of the siRNAs at later stages of development identified a stage 
at which knockdown of WT1 resulted not in renal agenesis, but 
rather in too much proliferation and a failure of differentiation, 
an effect with potential relevance to the development of a tumor. 
Immunostaining for WT1 protein showed that the knockdown 
was not absolute; low levels of WT1 (typical of early stages of renal 
development) were present in many cells, and a very few showed high 
levels of expression. 
In the same paper, two other proteins were targeted, the transcrip-
tion factor Pax2 and the signalling molecule Wnt4. Both showed 
knockdown, at least in mesenchymal tissues, and study of the expres-
sion of Wnt4, WT1 and Pax2 when each was knocked down was 
used to establish a likely hierarchy of their interactions.
The range of organs for which siRNA has been successfully used 
has steadily expanded since these early papers (Table 1). Some of 
these experiments have used intact organ rudiments, but others have 
used rudiments reconstructed from separated cells. The reason for 
this will be discussed in section 5 below.
siRNA in Organ Culture: The Pitfalls
Although the use of siRNA in organ culture has provided very 
valuable information in a number of systems, as recounted above and 
summarized in Table 1, it does not always work so well and several 
researchers involved in this field—and we include ourselves in this 
statement—have had to endure much frustration as well as occa-
sional success. If this were not so, there would have been far more 
siRNA organ culture papers published by now. The pitfalls of the 
technique fall into two categories—problems inherent in any siRNA 
experiment and problems caused specifically by organ culture. 
Problems inherent in any siRNA approach include the selection 
of effective and specific siRNA sequences, selection of a transfection 
method, monitoring the efficiency of knockdown and establishing 
the half-life of the protein. Much has been written elsewhere about 
design and selection of effective siRNA sequences and siRNAs for a 
large fraction of the genome can now be bought pre-tested off the 
shelf. In general, those that work in one cell will work in another, 
although there is always a small risk that one may be destroyed by 
cell-specific RNA editing systems.47 Once a siRNA has been 
Table 1 Examples of siRNA in organ culture
 Organ Target of siRNA Reference
 Atrioventricular canal Endoglin 35 
 Lung Fibronectin 29 
 Lung Hoxb5 36 
 Lung Fak 37 
 Kidney Fibronectin 29 
 Kidney Wt1, Wnt4, Pax2 30 
 Kidney GDNF 38 
 Ovary GDF-9 39 
 Palatal shelves Smad2 40 
 Re-constructed Ovary Wee-1 41 
 Salivary gland Fibronectin 29 
 Re-constructed Skin VEGF 42 
 Re-constructed Tooth Msx1, Dlx2 43 
 Re-constructed Thymus various 44 
 Urogenital Ridge Alks and Smads 45 
 Wolffian Duct Activin 46
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designed, it has to be delivered across the plasma membrane into 
the cell. Some mammalian cells will take up naked siRNA but inef-
ficiently, so that uneconomical amounts are needed. For this reason, 
siRNA is normally complexed to lipophilic carriers, which are avail-
able from a number of rival companies, each of which seems to 
claim that its own products are best. The ability of those companies 
to each make substantiated claims underlines the fact that different 
approaches suit different cells. Viruses can also be used to transfect 
siRNA (encoded as a hairpin loop or in miRNA backbone) into 
cells, although this is less likely to work in organ culture for reasons 
discussed below. Good advice on the choice of transfection method 
is available in the literature.48,49 It remains a feature of almost all 
siRNA experiments, though, that not all cells are transfected. A 
“70% knockdown,” for example, tends to reflect not all of the cells 
suffering a 70% reduction in expression but rather deep knockdown 
in about 70% of cells and 30% of cells being unaffected. This may 
make a real difference to the interpretation of an experiment.
Once an effective siRNA has been transfected into cells, it should 
lead to the destruction of its target mRNA (and no other). This will 
block protein synthesis, but the disappearance of the protein itself 
will depend on its half-life. The half-life of a protein is determined 
partially by the intrinsic properties of the protein but generally much 
more by the environment in which it finds itself, particularly with 
respect to proteases and ubiquitination mechanisms. Long-lived 
proteins can make siRNA experiments difficult to perform and to 
interpret, especially if the timing of the knockdown is important. 
Of course, conditional knockout models will suffer of this problem 
as well.
Protein half-life is not the only potential problem with knock-
down. The amount of a specific protein that is expressed by a cell 
is often under the control of feedback, and this is especially true of 
proteins whose concentration is critical to cellular and developmental 
events. These are the very types of proteins in which investigators 
tend to be interested. Feedback loops can be driven directly by a 
protein’s concentration or indirectly by consequences of the protein’s 
function and they can operate at the levels of transcription, transla-
tion, export and degradation.50-54 Attempts to knock down a protein 
by siRNA may therefore be thwarted, at least partially, by the cell 
‘fighting back’ and using post-translational methods to maintain a 
constant level of the protein.
The problems listed above can affect any siRNA experiment. 
The extra problems associated particularly with organ culture arise 
mainly from the three-dimensional nature of the tissue involved. In 
simple, two-dimensional culture of cells on the bottom of a flask, 
siRNA complexes or siRNA-encoding viruses can gain direct access 
to the surface of the cells. In three dimensional tissues or in artificial 
collagen gels, most cells are separated from the source of complexed 
siRNAs by diffusion pathways packed with extracellular matrix and 
sometimes a fully-formed basement membrane. These elements can 
act as barriers to diffusion or they can act as ‘traps’ that bind and 
concentrate siRNAs due to multiple low-affinity charge interac-
tions. The theoretical possibility of organ rudiments containing 
these barriers and traps can be tested empirically by using siRNA 
duplexes that are labelled with fluorophores such as Cy3. Such 
experiments typically show the distribution to be markedly uneven, 
even after days of culture (Fig. 2). The patterns can vary from organ 
to organ and also between developmental stages within one organ. 
In early salivary glands, for example, Cy3-labelled siRNA tends to 
be associated more with epithelial tissues than with mesenchymal29 
whereas in early kidneys it penetrates mesenchyme better than it 
does epithelia.30 A little later in kidney development, at the stage of 
mesenchymal condensation,55 an intra-mesenchymal barrier seems 
to form that interferes with penetration of siRNA into the conden-
sate (Fig 2).
These diffusion barriers have created serious problems to our own 
work in kidney and we have had to abandon, at least temporarily, 
attempts to knock down genes at late stages of renal development 
precisely because we see effective knockdown only in the most 
peripheral cells. Even at younger stages, we have found some genes 
easier to knock down than others—those genes that are not already 
switched on seem to be, in general, easier to knock down, presum-
ably because the problem of protein half life is greatly reduced when 
there is none of that protein present at time zero.
Approaches to More Reliable siRNA Techniques for  
Organ Culture
There are two, essentially opposite though not mutually exclusive, 
approaches to making siRNA-based gene knockdown work better in 
organ culture. The first is to adapt existing siRNA methods to use 
in organ culture while the second is to adapt existing organ culture 
methods for better susceptibility to siRNA treatment.
Many adaptations to the use of siRNA-mediated knockdown 
have already been described for two-dimensional cultures, but 
combinations of all these approaches may be needed to fully utilize 
the potential of siRNA in organ cultures. For transient knockdown 
Figure 2. Uneven penetration of labelled siRNAs into a cultured kidney rudi-
ment. An E12.5 kidney rudiment was cultured on a polycarbonate filter sup-
ported on a Trowell-type grid, and fluorescently-labelled siRNA, complexed 
to oligofectamine, was added to the medium. The siRNA has penetrated the 
loose mesenchyme (‘LM’) well and some seems to have reached at least the 
lumen of the ureteric bud (‘UB’), but it has substantially failed to enter the 
cap condensates (‘CC’).  This is disappointing because the cap condensates 
give rise to the nephrons of the kidney and studying the genetic mechanisms 
of nephron development is a priority in renal research. 
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experiments, the use of chemically synthesized siRNA molecules 
will usually be sufficient. However, when developmental processes 
take longer than transient knockdown will last, stable integration 
of siRNA expression constructs will be essential. In contrast to 
normal cell culture, simple selection for antibiotic resistance is not 
an option. Viral systems, especially Lentiviruses that infect both 
dividing and non-dividing cells with high efficiency, will be neces-
sary. Unfortunately, at least in kidney organ cultures, Lentiviruses are 
not capable of deeply penetrating the tissue (Berry and Hohenstein, 
unpublished data). If this problem can be solved (see below), induc-
ible systems will be needed to express the stably integrated siRNA 
cassette at the right time and place. The observation that RNA poly-
merase II-driven miRNA based vectors show improved knockdown 
at low copy numbers20 on top of the possibility of using a variety 
of regulatable systems as mentioned before would make this a likely 
system of choice.
Adaptation of organ culture techniques for siRNA generally 
involves disaggregating the organ rudiment so that cells are exposed 
to siRNA and then re-aggregating it so that it is still capable of orga-
notypic development.
An example of this approach is that developed by Park and 
colleagues, who wished to use siRNA for analysis of the development 
of ovarian follicles.41 To render ovarian cells susceptible to siRNA, 
these authors dissected ovaries and used enzymes to dissociate them 
into cell suspensions. They then used FuGene6 (Roche) to transfect 
either oocytes or somatic cells with siRNA, achieving transfection 
efficiencies of 40–50% and 50–60% for each cell type respectively 
and achieving knockdown of Wee1 expression to 30–40% of wild 
type levels. The transfected cells (and untransfected controls) were 
then aggregated with phytohaemagglutinin and coated with sodium 
alginate, which was then converted to a calcium alginate gel that 
encapsulated the reconstructed ‘ovaries’. These reconstructed ‘ovaries’ 
were then cultured for several days; even controls grew more slowly 
than unmolested organs, but the ones with Wee1 knockdown 
showed marked and specific developmental effects. 
Song and colleagues used a similar aggregation technique to knock 
down gene expression in tooth development.43 They removed molar 
tooth rudiments from E13.5 mouse embryos, separated their epithe-
lial and mesenchymal components and reduced the mesenchyme 
to a suspension of single cells with the aid of low calcium-medium. 
They then transfected them with Lentiviruses that encoded hairpin 
loops that would be processed by cells to yield siRNAs that targeted 
Msx1, Dlx2 and Barx1. They then centrifuged the cells to make a 
firm pellet and recombined this pellet with the epithelial compo-
nent of tooth rudiments (either as a complete epithelium or as 
suspended cells, which sorted spontaneously from the mesenchyme 
and re-formed its epithelial tissue). The recombination was cultured 
overnight in vitro and then in subrenal culture in vivo and controls 
developed into recognizable molars. Knockdown of Msx1 and Dlx2 
produced a phenocopy of their transgenic knockout phenotypes 
(arrest at tooth bud stage in the case of Msx1, normal development 
in the case of Dlx2). Knockdown of Barx1, for which no tooth data 
exist from conventional knockout mice, revealed a novel degenera-
tive phenotype. The detailed experiments in this report also revealed 
an interesting restriction to the re-aggregation approach: in the case 
of tooth rudiments, at least, it seems to be important that the time 
that mesenchymes spend separated from the epithelium must be 
minimized, because their ability to generate teeth in re-aggregated 
rudiments decreases rapidly with the time they spend alone. 
Reaggregation techniques connect strongly with the cutting edge 
of tissue engineering, and new methods for producing organotypic 
tissues from dispersed cells are being reported at an increasing rate 
in the tissue engineering literature. Depending on what question is 
being asked, many of these systems seem to offer a real potential for 
rendering a developing organ system accessible to siRNA. Examples 
include brain,56 cartilage,57 liver,58 tooth,59 thymus60 and vascular 
tissues.61
Conclusions
This is a fast-moving field, so any conclusions written at this 
stage must be regarded as both tentative and temporary. The use of 
siRNA has established itself in ordinary two-dimensional cell culture 
and it seems to us that with over a dozen research papers already 
published, from a variety of unconnected laboratories, the use of 
siRNA is also becoming established in organ culture. Its use here is 
not straightforward, however. The problems of ensuring adequate 
penetration are particularly acute and it seems that recent develop-
ments in disaggregation, transfection and reconstitution of organ 
rudiments offer a promising way forward and the combination of 
this with improved transfection methods offers most promise of all. 
The speed and flexibility of siRNA-based approaches offer substan-
tial advantages over the production of transgenic mice, particularly 
for preliminary experiments to gain enough information to know 
that a full transgenic (which has 100% knockout rather than a 
difficult-to-interpret knock-down) is worth making. In cases where 
it is difficult to generate a true loss-of-function knock-out model that 
inactivates all isoforms of a protein, siRNA-mediated knockdown 
may instead provide the means of testing the phenotypes of loss of 
specific isoforms. Other advantages of knockdown over knockout, as 
the possibility of generating allelic series of models to study dosage 
effects of genes,62 improving knockdown efficiencies by linking 
several target molecules in a single miRNA-based vector or even the 
possibility of linking target sequences against different proteins in 
the same construct for combined knockdown63 make knockdown 
experiments in organ cultures in many cases a complementation 
to knockout studies rather than a replacement. For this reason, we 
expect that the future will bring more applications in which siRNAs 
are used for high-throughout screens for genes that control the devel-
opment of organs, in much the same way that they are already being 
used to identify genes that control the development of invertebrate 
embryos.64
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